Catalan Pharma Iberica

Catalent is a leading global provider of delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. The company's Spanish operations, often referred to as Catalent Iberia, are centered in Martorelles and serve as a global excellence center for softgel technology and advanced oral delivery systems. Catalent is widely recognized for its proprietary Zydis fast-dissolve formulation and its extensive capabilities in clinical supply services and large-scale biologics production. In 2024, the company entered into a definitive agreement to be acquired by Novo Holdings for $16.5 billion to support the global manufacturing demand for GLP-1 medications. As a premier CDMO, Catalent supports thousands of customer programs across diverse therapeutic areas and modalities.